GLP-1-RAs lower risk of death and cardiovascular events in people with type 2 diabetes and IMIDs
Scientists from Arthritis Research Canada found a significant drop in all-cause mortality and major adverse cardiovascular events in people from the group who took glucagon-like peptide-1 receptor agonists.
Register for free access or login.
Canadian Healthcare Network is an independent online community for Canadian healthcare professionals in medicine and pharmacy. It is the online home of the Medical Post and Pharmacy Practice + Business.
Membership is free and allows doctors, pharmacists, nurses and many others to get the latest breaking news, updates on clinical guidelines and read (and even write) commentary from your healthcare peers.